WATCH: Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a study for patients with atypical CML, CNL, MDS/MPN-unclassifiable, and MDS/MPN-ring sideroblasts and thrombocytosis. #MPNSM | @MoffittNews
#MPNSM